Your browser is no longer supported. Please, upgrade your browser.
Settings
TGTX TG Therapeutics, Inc. daily Stock Chart
TGTX [NASD]
TG Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.92 Insider Own0.60% Shs Outstand75.40M Perf Week7.46%
Market Cap1.09B Forward P/E- EPS next Y-1.96 Insider Trans-6.61% Shs Float56.54M Perf Month-10.56%
Income-118.50M PEG- EPS next Q-0.44 Inst Own54.20% Short Float21.99% Perf Quarter54.01%
Sales0.20M P/S5428.80 EPS this Y-19.60% Inst Trans0.15% Short Ratio8.11 Perf Half Y81.13%
Book/sh1.01 P/B14.26 EPS next Y-15.30% ROA-111.90% Target Price30.00 Perf Year37.80%
Cash/sh1.12 P/C12.82 EPS next 5Y- ROE-145.60% 52W Range7.25 - 17.35 Perf YTD75.61%
Dividend- P/FCF- EPS past 5Y-6.70% ROI- 52W High-17.00% Beta1.20
Dividend %- Quick Ratio3.30 Sales past 5Y51.60% Gross Margin- 52W Low98.62% ATR0.73
Employees75 Current Ratio3.30 Sales Q/Q0.00% Oper. Margin- RSI (14)52.36 Volatility4.68% 5.74%
OptionableYes Debt/Eq0.00 EPS Q/Q3.60% Profit Margin- Rel Volume0.41 Prev Close14.70
ShortableYes LT Debt/Eq0.00 EarningsMar 16 BMO Payout- Avg Volume1.53M Price14.40
Recom1.50 SMA202.62% SMA501.01% SMA20029.17% Volume630,087 Change-2.04%
Mar-09-18Reiterated B. Riley FBR, Inc. Buy $21.50 → $27
Dec-01-17Resumed B. Riley FBR, Inc. Buy $21.50
Nov-14-17Resumed H.C. Wainwright Buy $33
Apr-25-17Initiated Jefferies Buy
Mar-06-17Reiterated FBR & Co. Outperform $24 → $26
Oct-06-16Resumed Brean Capital Buy $28
May-27-16Initiated SunTrust Buy $18
Dec-01-15Initiated FBR Capital Outperform $29
Sep-09-15Initiated Raymond James Strong Buy
Aug-12-15Resumed H.C. Wainwright Buy $22
Jun-19-15Reiterated Brean Capital Buy $22 → $28
Dec-11-14Reiterated ROTH Capital Buy $25 → $33
Dec-10-14Reiterated ROTH Capital Buy $25 → $33
Oct-27-14Initiated H.C. Wainwright Buy $17
Sep-25-14Reiterated Brean Capital Buy $19 → $22
Jul-22-14Reiterated Brean Capital Buy $13 → $19
Jul-02-14Reiterated MLV & Co Buy $10 → $16
Apr-04-14Initiated Brean Capital Buy $13
Mar-07-14Reiterated MLV & Co Buy $9 → $11
Nov-25-13Reiterated Ladenburg Thalmann Buy $8 → $12
Apr-20-18 08:03AM  3 Biotech Stocks With Major Catalysts Incoming Motley Fool
Apr-18-18 09:00AM  TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Companys BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Apr-16-18 07:00AM  Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline GlobeNewswire
Mar-26-18 07:30AM  TG Therapeutics, Inc. to Present at the Needham 17th Annual Healthcare Conference GlobeNewswire
Mar-15-18 07:30AM  TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-09-18 02:21PM  Edited Transcript of TGTX earnings conference call or presentation 8-Mar-18 1:30pm GMT Thomson Reuters StreetEvents
Mar-08-18 09:36AM  TG Therapeutics reports 4Q loss Associated Press +7.87%
07:30AM  TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017 Financial Results and Business Update GlobeNewswire
Mar-06-18 07:30AM  TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update GlobeNewswire
Mar-02-18 07:30AM  TG Therapeutics, Inc. to Present at Upcoming Investor Conferences GlobeNewswire
Feb-27-18 07:07PM  Cramer's lightning round: Wall Street youngsters are weig... CNBC Videos
06:50PM  Cramer's lightning round: Wall Street youngsters are weighing on oil stocks CNBC
07:45AM  New Research Coverage Highlights Atkore International Group, Virtusa, Aceto, Cullen/Frost Bankers, TG Therapeutics, and Boingo Wireless Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Feb-21-18 05:18PM  Why TG Therapeutics Stock Jumped 10% Today Motley Fool +9.92%
07:30AM  TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology GlobeNewswire
Feb-07-18 11:23AM  Harry Boxers three stocks breaking out on earnings news MarketWatch
Feb-05-18 08:30AM  Todays Research Reports on Trending Tickers: Array BioPharma and TG Therapeutics ACCESSWIRE
Feb-04-18 11:02AM  Growth Stocks Investors Love Simply Wall St.
08:01AM  3 Boom-or-Bust Biotech Stocks to Buy in 2018 Motley Fool
Feb-02-18 06:30AM  TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the Third Annual ACTRIMS Forum 2018 GlobeNewswire
Jan-24-18 07:30AM  TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018 GlobeNewswire
Jan-11-18 05:02PM  Why TG Therapeutics Rallied 15.7% Today Motley Fool +15.76%
Jan-08-18 07:30AM  TG Therapeutics, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
07:30AM  TG Therapeutics and Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program for the Treatment of Hematologic Malignancies GlobeNewswire
Jan-03-18 11:02AM  January Top Growth Stocks Simply Wall St. +5.71%
Dec-20-17 07:35AM  Market Trends Toward New Normal in TG Therapeutics, Boingo Wireless, Dave & Buster's Entertainment, Flagstar, Superior Industries International, and Benchmark Electronics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
07:22AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : December 20, 2017 Capital Cube
Dec-11-17 02:12PM  ETFs with exposure to TG Therapeutics, Inc. : December 11, 2017 Capital Cube
10:38AM  TG Therapeutics Inc (TGTX): Does -30.2% EPS Decline Lately Make It An Underperformer? Simply Wall St.
07:00AM  TG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Dec-08-17 08:06AM  TG Therapeutics, Inc. Recaps Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting GlobeNewswire
Nov-30-17 02:28PM  ETFs with exposure to TG Therapeutics, Inc. : November 30, 2017 Capital Cube
Nov-29-17 08:42AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-27-17 07:30AM  TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma GlobeNewswire
Nov-22-17 08:20AM  Todays Research Reports on Trending Tickers: MannKind Corporation and TG Therapeutics ACCESSWIRE
Nov-14-17 12:29PM  Edited Transcript of TGTX earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-08-17 08:03AM  TG Therapeutics reports 3Q loss Associated Press
07:30AM  TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 07:30AM  TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update GlobeNewswire -5.42%
Nov-01-17 09:30AM  TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting GlobeNewswire
Oct-31-17 07:30AM  TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 (ublituximab) in Multiple Sclerosis GlobeNewswire
Oct-27-17 07:30AM  TG Therapeutics, Inc. Announces Additional Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
Oct-26-17 07:30AM  TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
Oct-17-17 08:10AM  Today's Research Reports on Stocks to Watch: Aratana Therapeutics and TG Therapeutics ACCESSWIRE -9.16%
Oct-16-17 02:20PM  Why TG Therapeutics Is Tumbling 15% Today Motley Fool -15.68%
07:30AM  TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
07:30AM  TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 Trial GlobeNewswire
07:30AM  TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial GlobeNewswire
Oct-12-17 08:24AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : October 12, 2017 Capital Cube
Oct-05-17 07:30AM  TG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical Development GlobeNewswire
Sep-29-17 08:47AM  Why You Need To Look At This Factor Before Buying TG Therapeutics Inc (TGTX) Simply Wall St.
07:30AM  TG Therapeutics Announces TGR-1202 (umbralisib) Selected For Grant from the National Multiple Sclerosis Society to Support the Development of TGR-1202 as an Oral B-cell Targeted Treatment Option in Progressive Multiple Sclerosis (PMS) GlobeNewswire
Sep-28-17 10:30AM  TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : September 28, 2017 Capital Cube
Sep-27-17 08:17AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : September 27, 2017 Capital Cube
Sep-21-17 07:30AM  TG Therapeutics, Inc. to Present at Upcoming Investor Conferences GlobeNewswire
Sep-15-17 07:30AM  TG Therapeutics, Inc. Announces the Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with Multiple Sclerosis Are Now Open for Enrollment GlobeNewswire
Sep-13-17 11:01AM  Should You Buy TG Therapeutics Inc (TGTX) Now? Simply Wall St.
Sep-05-17 07:30AM  TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial GlobeNewswire
Sep-01-17 07:30AM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
Aug-31-17 09:31PM  ETFs with exposure to TG Therapeutics, Inc. : September 1, 2017 Capital Cube
Aug-24-17 10:13AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-14-17 08:28AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : August 14, 2017 Capital Cube
Aug-13-17 02:31AM  Edited Transcript of TGTX earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 07:30AM  TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial GlobeNewswire
Aug-09-17 01:01PM  TG Therapeutics reports 2Q loss Associated Press
07:30AM  TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results GlobeNewswire
05:50AM  Investor Network: TG Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 05:04PM  What's Behind TG Therapeutics Inc.'s 14.4% Rally in July? Motley Fool
07:30AM  TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2017 Financial Results and Business Update GlobeNewswire
Aug-03-17 11:37PM  TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : August 4, 2017 Capital Cube -5.88%
Aug-02-17 09:13AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : August 2, 2017 Capital Cube
Aug-01-17 07:30AM  TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS) GlobeNewswire
Jul-25-17 01:35PM  ETFs with exposure to TG Therapeutics, Inc. : July 25, 2017 Capital Cube -5.81%
Jul-21-17 08:37AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : July 21, 2017 Capital Cube
Jul-14-17 05:08PM  ETFs with exposure to TG Therapeutics, Inc. : July 14, 2017 Capital Cube
Jun-28-17 09:02AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : June 28, 2017 Capital Cube
Jun-26-17 07:30AM  TG Therapeutics, Inc. Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress GlobeNewswire
07:00AM  TG Therapeutics Recaps Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 3rd Congress of the European Academy of Neurology GlobeNewswire
Jun-21-17 06:48PM  Cramer's lightning round: This defeated stock is like flypaper CNBC
Jun-16-17 05:45AM  TG Therapeutics, Inc. Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma GlobeNewswire
Jun-15-17 04:21PM  New Data Shows TG Therapeutics Could Be Onto Something Big Motley Fool
03:27PM  ETFs with exposure to TG Therapeutics, Inc. : June 15, 2017 Capital Cube
08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on BioCryst Pharmaceuticals and TG Therapeutics Accesswire
04:00AM  TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma GlobeNewswire
Jun-14-17 12:00PM  TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma GlobeNewswire +5.16%
Jun-13-17 09:29AM  Excitement from ASCO: TG Thereapeutics, Loxo Oncology, and Bluebird Bio Motley Fool
08:51AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : June 13, 2017 Capital Cube
07:30AM  TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress GlobeNewswire
Jun-08-17 07:30AM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma GlobeNewswire +5.69%
Jun-06-17 08:49AM  Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock? Zacks
07:30AM  TG Therapeutics, Inc. to Present at the 2017 Jefferies Global Healthcare Conference GlobeNewswire
Jun-05-17 02:50PM  ETFs with exposure to TG Therapeutics, Inc. : June 5, 2017 Capital Cube -6.14%
10:56AM  U.S. stocks look for direction in shadow of U.K. terror attacks MarketWatch
09:43AM  Stocks to Watch: Apple, Snap, Herbalife The Wall Street Journal
09:37AM  UPDATE: TG Therapeutics stock rises 4% on positive late-stage cancer trial results MarketWatch
09:00AM  TG Therapeutics, Inc. Announces Follow-Up Data from the Chemo-Free Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
08:00AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics Accesswire
Jun-03-17 06:00PM  TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
Jun-02-17 05:37PM  Why TG Therapeutics Inc Jumped Higher Today Motley Fool +17.37%
07:30AM  TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Power Sean ACFO, Secretary and TreasurerJan 02Sale8.5032,006272,051485,458Jan 03 05:25 PM
Power Sean ACFO, Secretary and TreasurerJun 19Sale11.0430,000331,200447,464Jun 19 06:05 PM
Power Sean ACFO, Secretary and TreasurerJun 16Sale11.1429,976333,933477,464Jun 19 06:05 PM